CDC Website CDC Website

To Join the NPIN community or

You are here

City Agencies

Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical and preclinical/non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis. 
 

Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, and preclinical and/non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis. 

Ending the HIV Epidemic: A Plan for America Ryan White HIV/AIDS Program Parts A and B

The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2020 Ending the HIV Epidemic: A Plan for America — Ryan White HIV/AIDS Program Parts A and B. The purpose of this program is to focus resources in 48 counties, Washington, D.C., San Juan, Puerto Rico, and seven states with substantial rural HIV burden (hereafter referred to as “jurisdictions”) to implement strategies, interventions, approaches, and core medical and support services to reduce new HIV infections in the United States.

Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HIV-associated neurological disorders (HAND) in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines. 
 

Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Such responses may be operative in mycobacterial infection, or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected and/or uninfected individuals.

Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 - Clinical Trials Not Allowed)

Edith Jickling's picture

The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology. 
 

Adipogenesis, Adipocyte Function and Obesity Following HIV Infection, Antiretroviral Therapy, or Pre-Exposure Prophylaxis (R01 Clinical Trial Optional)

The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that there are unique mechanisms contributing to the development of obesity in PWH versus people without HIV. Furthermore, the biology of the adipocytes might be altered in overweight or obese PWH versus overweight or obese people without HIV.

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)

NIDA is interested in research that addressing research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited.

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)

Edith Jickling's picture

NIDA is interested in research that addressing research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited.

Pages

Subscribe to RSS - City Agencies